Table 4.
Treatment-related AEs in patients with advanced NSCLC.
| AEs | Total patients (n=128) | Apatinib dose = 500mg/d (n=104) | Apatinib dose > 500mg/d (n=24) | |||
|---|---|---|---|---|---|---|
| Total | Grade3 | Total | Grade3 | Total | Grade3 | |
| Hypertension | 48 (37.5%) | 7 (5.5%) | 39 (37.5%) | 4 (3.8%) | 9 (37.5%) | 3 (12.5%) |
| Proteinuria | 35 (27.3%) | 6 (4.7%) | 31 (29.8%) | 4 (3.8%) | 4 (16.7%) | 2 (8.3%) |
| HFS | 30 (23.4%) | 0 (0.0%) | 24 (23.1%) | 0 (0.0%) | 6 (25.0%) | 0 (0.0%) |
| Fatigue | 24 (15.2%) | 2 (1.6%) | 18 (17.3%) | 2 (1.9%) | 6 (25.0%) | 0 (0.0%) |
| Hematologic toxicities | 21 (16.4%) | 5 (3.9%) | 16 (15.4%) | 4 (3.8%) | 5 (20.8%) | 1 (4.2%) |
| Anorexia | 21 (15.6%) | 3 (2.3%) | 15 (14.4%) | 2 (1.9%) | 6 (25.0%) | 1 (4.2%) |
| Nausea and vomiting | 19 (14.8%) | 1 (0.8%) | 13 (12.5%) | 0 (0.0%) | 6 (25.0%) | 1(4.2%) |
AEs, adverse effects; HFS, hand-foot syndrome.